Ekaterini Maida is a Nuclear Physician, MD, Deputy Director of the Department of Nuclear Medicine & Department of PET/CT, Athens Medical Center. Scientific Director of the Department of Nuclear Medicine PET/CT, Inter-Balkan Medical Center of Thessaloniki.

Ekaterini Maida graduated in 1998 from the Athens Medical School. He trained in Internal Medicine at the Hospital Lyon Sud, in Lyon, France, from 2000 to 2001. He trained and obtained the title of Medical Specialty in Nuclear Medicine at the General Hospital “Alexandra” in 2005. He obtained a postgraduate degree from the European Nuclear Medicine School – INSTN course – in biology, radiation dosimetry and radiation protection, radiopharmaceuticals and Clinical Nuclear Medicine, Saclay, France.

She was trained and specialized in the clinical applications and interpretation of PET/CT as a curator-Assisstant Hospitalier Universitaire (AHU) – in the Nuclear Medicine Department of the Groupement Hospitalier Est, Université Claude Bernard Lyon1 and the PET/CT Department of the Leon Berard Cancer Center in Lyon, France (2005-2006). Her clinical and research interest focuses on the applications of PET in oncology, as well as on issues of radiation attenuation correction. She is a member of the Hellenic Society of Nuclear Medicine and Molecular Imaging, of which she has served as a member of the Board and treasurer since 1/2025, of the European Association of Nuclear Medicine and of the Ordre Medical de Lyon in France.

In 2007, she took on the position of curator of the Nuclear Medicine Department at the Athens Medical Center in Maroussi, while a year later she took on the position of associate of the PET/CT Department, departments in which she works to this day as deputy director. For many years, she has been one of the main diagnosticians of PET/CT examinations. She is responsible for therapeutic applications of Nuclear Medicine at the Athens Medical Center in the field of Liver Radioembolization and Radiohymenolysis, while more recently she directs the Department of Radiopeptide Therapeutic Applications (Theranostics) for prostate cancer.